Melanoma: Immediate Impact of 2014 ASCO Presentations on Clinical Practice

Introduction

In an effort to provide you with timely market feedback from ASCO 2014, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ from the meeting. This third report explored presentations in Melanoma.

OncoPoll™ Methodology

  • Primary research phase involved a global survey to verified and validated medical oncologists and multi-disciplinary physicians with an identified clinical interest in melanoma utilizing targeting parameters within the proprietary MDoutlook® global cancer treater database
  • Timing: June 2014. Launched three days after close of 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL., May 30-June 3, 2014
  • Fielding via <10 minute long interactive internet survey utilizing proven effective methodology via the MDoutlook survey tool
  • Links to discussed abstracts on the ASCO website were provided within the survey
  • Reponses at data collection: 48 on June 24th
  • No financial incentives provided for participation

Geographic Distribution of Respondents

Attendance at 2014 ASCO Annual Meeting

Key Conclusions

  • 60% of survey respondents attended this year’s ASCO annual meeting
  • Greater proportion of attendees than in previous years (typically has been a 50/50 split)

Survey Participants’ Melanoma Patient Flow: Averaged 45 Total Cases Each Quarter

Key Conclusions

  • Survey participants* averaged 45 total cases of melanoma in the last 3 months
  • The highest average proportion of cases were represented by stage IV M1c (11 patients or 24%)
    • Oncologists saw eight or fewer patients on average for all other stages over the span of three months

* Survey Participants = Medical Oncologists with an identified clinical interest in melanoma

Impact of New Monoclonal Antibodies Targeting the PD-1/PD-1L Axis for Melanoma Immunotherapy Treatments

Key Conclusions

  • Considering both clinical efficacy and potential adverse events, oncologists have given nivolumab + ipilimumab, nivolumab alone, and pembrolizumab very high ratings
    • Nivolumab + ipilimumab: 5.71 (out of 7)
    • Nivolumab alone: 5.35
    • Pembrolizumab: 5.22
    • Pidilizumab was rated the lowest by oncologists, with a score of 4.39 out of 7

Forecasting the Integration of Immune Checkpoint Inhibitor Targeting PD-1/PD-1L Axis for Metastatic Melanoma Patients

Key Conclusions

  • The highest proportion of metastatic melanoma patients that would receive an immune checkpoint inhibitor targeting the PD-1/PD-1L axis are BRAF wild-type patients in their 1st line of treatment (58%) vs. 31% of BRAF V600E/K patients
  • Equal proportions (45%) of BRAF V600E/K and BRAF wild-type patients would receive an immune checkpoint inhibitor targeting the PD-1/PD-1L axis in the 2nd line of treatment
    • Progressively fewer patients would receive an immune checkpoint inhibitor in subsequent lines of treatment

Importance of Ipilimumab in the Adjuvant Setting for Metastatic Melanoma

Key Conclusions

  • 75% of oncologists believe ipilimumab will be somewhat important or important as an adjuvant treatment for stage III disease due to improvements in relapse-free survival (RFS) without corresponding benefits in overall survival (OS)
  • 93% of oncologists believe ipilimumab will be somewhat important to very important as an adjuvant treatment for stage III disease due to improvements in RFS and OS

Impact of the OPTIM Trial – T-VEC’s Effect on Unresectable Melanoma

Key Conclusions

  • The majority of oncologists (68%) believe that, if gaining regulatory approval, T-VEC will only impact a minority of patients with unresectable melanoma
  • Only 18% of oncologists believe that T-VEC will impact a majority of patients with unresectable melanoma

Conclusions: Impact of ASCO 2014 on Clinical Practices for Melanoma

  • Survey participants averaged 45 cases of melanoma in the last 3 months
    • The highest proportion of cases were represented by stage IV M1c (24%)
  • Considering both clinical efficacy and potential adverse events, oncologists have given nivolumab + ipilimumab, nivolumab alone, and pembrolizumab very high ratings (>5 out of 7)
  • The highest proportion of metastatic melanoma patients that would receive an immune checkpoint inhibitor targeting the PD-1/PD-1L axis are BRAF wild-type patients in their 1st line of treatment (58%) vs. 31% of BRAF V600E/K patients
  • 75% of oncologists believe Ipilimumab will be somewhat important or important as an adjuvant treatment for stage III disease with only improvements in relapse-free survival (RFS)
  • 93% of oncologists believe Ipilimumab will be somewhat important to very important as an adjuvant treatment for stage III disease with improvements in RFS and OS
  • The majority of oncologists (68%) believe that, if gaining regulatory approval, T-VEC will only impact a minority of patients with unresectable melanoma

For a more detailed analysis report, please click here to download the full report.

Submitted by Robert Stephan, Sr. Director Medical Services and Strategy; Jessica Harnisch, Assoc. Global Medical Analyst; and Jan Heybroek, President MDoutlook.

article register

Recent Posts

Recent Comments

Archives

Categories

Post a Comment

You must be logged in to post a comment